Investigators established a rat model of bone cancer pain by intratibial inoculation of luciferase-labeled MADB106 cells. They then administered Shikonin intrathecally and measured nociception with mechanical and thermal assays. The compound produced dose- and time-dependent antinociceptive effects; the reported ED50 was 29.80 μg/kg. Short, targeted testing showed analgesia without an apparent deficit on rotarod performance, indicating that gross motor coordination was not obviously impaired by treatment.
Behavioral assessments extended beyond simple withdrawal thresholds. The authors used CatWalk gait analysis to quantify functional impairment and deployed standard anxiety-related paradigms — open field, elevated plus maze, and light/dark box — to capture pain-associated affective changes. Data indicated improvement across several of these readouts after intrathecal Shikonin, suggesting benefits to both sensory and behavioral dimensions of the pain phenotype.
The study team performed transcriptomic sequencing on the spinal dorsal horn to identify molecular pathways responsive to treatment. Their analysis singled out Igf2 as a candidate gene whose expression changed with Shikonin exposure. During disease progression, investigators observed increases in spinal IGF2 and elevated phosphorylation of p38 MAPK, pointing to activation of a signaling axis in the dorsal horn during bone cancer pain.
Shikonin treatment reduced both IGF2 expression and p38 phosphorylation in spinal dorsal horn tissue. The pattern of molecular changes aligned with behavioral improvements, forming the basis for subsequent mechanistic probing.
The analgesic effect extended to gait and affective measures. CatWalk metrics showed correction of gait abnormalities that accompanied tumor-bearing limbs, and anxiety-like behaviors associated with persistent pain were attenuated in the tested paradigms. The authors emphasized that rotarod performance did not show an apparent impairment following Shikonin, a key observation when evaluating spinal interventions that might carry motor side effects.
Investigators reported that combined behavioral, gait, and affective metrics improved, suggesting a multi-domain benefit in this rat model. The source did not provide detailed numerical outcome tables in the abstract, so exact magnitudes and time courses of each behavioral endpoint were not reported there.
To test causality, the group used intrathecal IGF2 siRNA to knock down spinal IGF2 and applied the p38 inhibitor Adezmapimod (SB203580) as a pharmacologic probe. IGF2 knockdown reproduced the analgesic and behavioral effects observed with Shikonin, and it reduced p38 phosphorylation. By contrast, p38 inhibition produced key behavioral improvements without a marked change in IGF2 expression.
Combined administration of Shikonin with either IGF2 knockdown or p38 inhibition produced no significant additional behavioral benefit, the authors reported. Those non-additive effects support a model in which Shikonin acts, at least in part, via an IGF2-associated p38 MAPK signaling axis in the spinal dorsal horn. The abstract did not specify siRNA dosing, timing, or off-target assessments; those methodological details appear in the full manuscript but are not in the source abstract.
Molecular assays including western blotting, quantitative PCR, and ELISA were used to profile inflammatory mediators and signaling proteins in spinal tissue. Treatment with Shikonin was associated with decreased levels of IL-6, IL-1β, and TNF-α in the dorsal horn. The authors linked cytokine suppression to reduced p38 phosphorylation and lower IGF2 expression, building a mechanistic connection between anti-inflammatory changes and behavioral outcomes.
The abstract does not report whether peripheral tumor burden or bone pathology were altered by Shikonin beyond histologic characterization and bioluminescence imaging used to monitor tumor development. Those data likely appear in the full text but were not summarized in the abstract provided.
The authors posted this report as a preprint on bioRxiv; the work has not undergone peer review. That status requires independent replication and critical appraisal before translational or clinical claims can be advanced. The abstract did not provide sample sizes, detailed dosing regimens for siRNA or p38 inhibitor, safety pharmacology beyond rotarod testing, or long-term outcome data — those methodological specifics are not reported in the abstract and should be consulted in the full manuscript.
Key open questions remain: can systemic administration reproduce the intrathecal effects, what are off-target actions of Shikonin, and how durable are analgesic responses with repeated dosing? The study furnishes mechanistic evidence linking IGF2 and p38 MAPK to analgesia in this model, but further validation, dose–response and safety profiling, and peer review are required to evaluate translational potential.